| Tradename: | Corectim |
| Atc Prefix: | D11 |
| Atc Suffix: | AH11 |
| Legal Status: | JP: Rx-only |
| Cas Number: | 1263774-59-9 |
| Pubchem: | 50914062 |
| Chemspiderid: | 59718502 |
| Drugbank: | DB16133 |
| Kegg: | D11046 |
| Unii: | 9L0Q8KK220 |
| Synonyms: | JTE-052; JTE-052A |
| Iupac Name: | 3-[(3''S'',4''R'')-3-Methyl-7-(7''H''-pyrrolo[2,3-d]pyrimidin-4-yl)-1,7-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile |
| C: | 16 |
| H: | 18 |
| N: | 6 |
| O: | 1 |
| Stdinchi: | 1S/C16H18N6O/c1-11-8-22(13(23)2-5-17)16(11)4-7-21(9-16)15-12-3-6-18-14(12)19-10-20-15/h3,6,10-11H,2,4,7-9H2,1H3,(H,18,19,20)/t11-,16-/m0/s1 |
| Stdinchikey: | LOWWYYZBZNSPDT-ZBEGNZNMSA-N |
| Smiles: | C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2 |
Delgocitinib, sold under the brand name Corectim, is a medication used for the treatment of autoimmune disorders and hypersensitivity, including inflammatory skin conditions.[1] Delgocitinib was developed by Japan Tobacco and approved in Japan for the treatment of atopic dermatitis.[1] In the United States, delgocitinib is in Phase III clinical trials and the Food and Drug Administration has granted delgocitinib fast track designation for topical treatment of adults with moderate to severe chronic hand eczema.[2]
Delgocitinib works by blocking activation of the JAK-STAT signaling pathway which contributes to the pathogenesis of chronic inflammatory skin diseases.[3]
In July 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Anzupgo, intended for the treatment of chronic hand eczema.[4] [5] The applicant for this medicinal product is LEO Pharma A/S.